Idenix’s Pain Is Achillion’s Gain
Long Ideas - Idenix Pharmaceuticals (NASDAQ:IDIX) announced today that the FDA has placed its lead compound for hepatitis C, IDX-184, on partial clinical hold. According to IDIX, the … Continue Reading
Read nowAuthor Archives: Editorial Staff
Preliminary Data from Phase I Trials Look Good for Lexicon Pharmaceuticals
- Lexicon Pharmaceuticals (NASDAQ:LXRX) released findings from two separate Phase I trials this morning for Rheumatoid Arthritis and glaucoma. LX2931 was studied for its safety and … Continue Reading
Read nowNeuralstem Hanging on as Investors Lose Interest
- Neuralstem, Inc. (NYSEAMEX:CUR) investors will have noted the biotech company’s slow share decline this year. From September 2011’s high of $1.52, shares took an ambling … Continue Reading
Read nowForest Vote Today May Determine Company's Future, Alienate Icahn
- The battle continues in activist-investor Carl Icahn’s fevered examination of Forest Laboratories (NYSE:FRX). Today’s proxy vote will be this year’s penultimate decision; shareholders will be … Continue Reading
Read nowCollaborative NSCLC Treatment Begins Phase I/II Study
- The Debiopharm Group and Curis, Inc (NASDAQ:CRIS) announced this morning the beginning of a Phase I/II clinical study of Debiopharm’s development-stage Debio 0932, a second-generation … Continue Reading
Read nowF2Q Likely An Anomaly; COO Preparing To Show Investors With F3Q Results
Long Ideas - The Cooper Companies (NYSE:COO) became known as a “sleep at night” stock, with this leading contact lens provider beating estimates 8 quarters in a row. … Continue Reading
Read nowActivity In Peregrine May Indicate A Raise Is Coming
- Peregrine Pharmaceuticals (NASDAQ:PPHM) broke out of its 52-week range Monday on chatter over a possible drug company partnership for lead cancer compound, bavituximab. Shares were … Continue Reading
Read now